Functional Dyspepsia: Rome IV Subtypes, H. pylori Testing, and Step-Up Therapy
A practical guideline for evaluating dyspepsia, applying age-based test-and-treat or endoscopy-first strategies, and managing PDS and EPS subtypes with PPIs, prokinetics, and gut-brain neuromodulators.
Executive Summary
Functional dyspepsia (FD) is a common disorder of gut-brain interaction affecting 10-20% of adults, defined by Rome IV criteria as bothersome postprandial fullness, early satiation, epigastric pain, or epigastric burning without structural explanation. Two subtypes guide therapy: postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS). Initial management depends on age and alarm features—patients under 60 without alarms undergo H. pylori test-and-treat in higher-prevalence regions, while those 60+ require upfront endoscopy. Pharmacotherapy progresses from PPIs (particularly EPS) and prokinetics (particularly PDS) to neuromodulators (tricyclic antidepressants, mirtazapine) and gut-brain behavioral therapy in refractory disease.
S1. Pathophysiology and Subtype Definitions
Disorder of Gut-Brain Interaction
Functional dyspepsia, like irritable bowel syndrome, is reframed under Rome IV as a disorder of gut-brain interaction with measurable peripheral and central abnormalities. Pathophysiologic contributors include impaired gastric accommodation (failure of fundus relaxation following a meal, found in 30-40% of patients), delayed gastric emptying (in 20-30%, particularly PDS), visceral hypersensitivity to gastric distension (in 30-40%), duodenal eosinophilia and low-grade inflammation, increased intestinal permeability, gastric and duodenal microbiota changes, and central pain processing alterations. Genetic factors, prior gastroenteritis (post-infectious FD parallels post-infectious IBS), psychological stress, and early life adversity modulate susceptibility.
Postprandial Distress Syndrome (PDS)
PDS is characterized by symptoms induced or worsened by meals: bothersome postprandial fullness (heavy or full feeling after a normal-sized meal) or bothersome early satiation (inability to finish a normal-sized meal). Pathophysiology emphasizes impaired accommodation and delayed gastric emptying. Patients often describe a relationship between symptoms and meal volume or composition. Distinguishing PDS from gastroparesis requires gastric emptying scintigraphy when objective evaluation is needed; many patients have mild emptying abnormalities that fall below the gastroparesis threshold.
Epigastric Pain Syndrome (EPS)
EPS is characterized by bothersome epigastric pain or epigastric burning that is intermittent (at least once weekly), localized to the epigastrium, not generalized or occurring in other abdominal/chest regions, and not relieved by defecation or passage of flatus (which would suggest IBS). Pain may or may not be related to meals. Pathophysiology emphasizes visceral hypersensitivity, mucosal inflammation (duodenal eosinophilia), and central pain processing. EPS responds preferentially to PPIs and neuromodulators.
Subtype Overlap and Variability
Approximately 30-40% of patients meet criteria for both PDS and EPS simultaneously (overlap subtype). Subtype assignments may shift over time. Co-existence with gastroesophageal reflux disease, irritable bowel syndrome, and chronic nausea is common; multiple Rome IV diagnoses may apply concurrently. The therapeutic implication is that combination therapy (e.g., PPI plus prokinetic, PPI plus neuromodulator) is often necessary in patients with overlapping symptoms or partial response to single-agent therapy.
S2. Rome IV Criteria and Differential Diagnosis
Rome IV Criteria for Functional Dyspepsia
Differential Diagnosis
| Condition | Discriminating Features | Workup |
|---|---|---|
| Peptic ulcer disease | Burning epigastric pain, nocturnal symptoms, NSAID/H. pylori | Upper endoscopy with biopsy |
| GERD with overlap | Heartburn, regurgitation as predominant symptoms | Symptom-based; PPI trial; pH monitoring if refractory |
| Gastric / esophageal cancer | Age >60, weight loss, dysphagia, anemia, family history | Upper endoscopy with biopsy |
| Gastroparesis | Postprandial fullness, nausea, vomiting; diabetes, post-surgical, idiopathic | 4-hour gastric emptying scintigraphy >10% retention |
| Biliary colic / chronic cholecystitis | Right upper quadrant pain, post-fatty meal, radiation to back/scapula | Right upper quadrant ultrasound; HIDA if normal US |
| Chronic pancreatitis | Epigastric pain radiating to back, weight loss, steatorrhea, alcohol/genetic | CT or MRCP; fecal elastase <200; secretin MRCP |
| Pancreatic cancer | Painless jaundice or epigastric pain to back, weight loss, new diabetes | CT pancreas protocol; CA 19-9; EUS with FNA if mass |
| Mesenteric ischemia (chronic) | Postprandial pain, weight loss, food fear, atherosclerotic risk factors | CT or MR angiography of mesenteric arteries |
| Celiac disease (atypical) | Bloating, diarrhea, anemia, family history | tTG-IgA + total IgA; duodenal biopsy |
| Eosinophilic gastritis | Persistent symptoms, peripheral eosinophilia, atopy | Upper endoscopy with biopsy (eosinophil count) |
| Medication-induced | NSAIDs, bisphosphonates, iron, potassium, antibiotics | Medication review and trial of cessation |
| Cardiac (atypical angina) | Exertional symptoms, radiation to arm/jaw, cardiovascular risk | ECG, troponin, stress testing if appropriate |
S3. Diagnostic Workup, Endoscopy, and H. pylori Testing
Initial Evaluation
History should establish symptom predominance (PDS vs EPS), duration, alarm features, GERD-like features (heartburn, regurgitation), bowel habit (IBS overlap), prior infections, medications (NSAIDs, bisphosphonates, iron, K, calcium channel blockers), and psychosocial factors. Examine for epigastric tenderness, palpable mass, lymphadenopathy (Virchow node, Sister Mary Joseph), jaundice, and signs of weight loss. Initial laboratories include CBC (anemia, eosinophilia), CMP (renal/hepatic function), TSH (hyper/hypothyroidism), and celiac serology (tTG-IgA + total IgA) in high-prevalence populations or with diarrhea/bloating overlap.
Age-Based Endoscopy Strategy
H. pylori Testing
| Test | Sensitivity | Specificity | Notes |
|---|---|---|---|
| Urea breath test (13C or 14C) | 95-100% | 95-100% | Gold standard for active infection; hold PPI 2 weeks, antibiotics/bismuth 4 weeks |
| Stool antigen test | 94% | 97% | Equivalent to UBT; same hold periods; preferred for confirmation of eradication |
| Endoscopic biopsy (RUT) | 85-95% | 95-100% | Use during scheduled endoscopy; reduced sensitivity with PPI/recent bleeding; sample antrum + corpus |
| Endoscopic biopsy (histology) | 95% | 95-100% | Use during scheduled endoscopy; can identify atrophy, intestinal metaplasia, dysplasia |
| Serology (IgG) | 85% | 79% | NOT recommended for active infection or eradication confirmation; cannot distinguish active from past |
H. pylori Eradication Regimens
First-line therapy depends on local clarithromycin resistance pattern. Where clarithromycin resistance is <15%, standard triple therapy may be acceptable; in most regions resistance now exceeds 15%, mandating bismuth quadruple or vonoprazan-based therapy as first-line. Confirm eradication 4 weeks after completion using stool antigen or urea breath test (off PPI 2 weeks).
| Regimen | Components | Duration | Eradication |
|---|---|---|---|
| Bismuth quadruple (preferred first-line) | PPI BID + bismuth subsalicylate 525 mg QID + metronidazole 500 mg TID + tetracycline 500 mg QID | 10-14 days | 85-93% |
| Vonoprazan triple (where available) | Vonoprazan 20 mg BID + amoxicillin 1000 mg BID + clarithromycin 500 mg BID | 14 days | 87-90% |
| Vonoprazan dual (penicillin-tolerant) | Vonoprazan 20 mg BID + amoxicillin 1000 mg TID | 14 days | 80-84% |
| Standard triple (only if clarithro resist <15%) | PPI BID + clarithromycin 500 mg BID + amoxicillin 1000 mg BID | 14 days | 70-85% |
| Levofloxacin rescue (after 1 failure) | PPI BID + levofloxacin 500 mg daily + amoxicillin 1000 mg BID | 14 days | 70-80% |
| Rifabutin rescue (after 2 failures) | PPI BID + rifabutin 150 mg BID + amoxicillin 1000 mg BID | 10-12 days | 70-75% |
Stepwise management
Functional dyspepsia: step-up treatment
For adults with FD after workup, including upper endoscopy when indicated.
Start: medication review and H. pylori test-and-treat
- Stop NSAIDs and other aggravating drugs when possible
- Urea breath test, stool antigen, or biopsy at endoscopy; not serology
- Hold PPI 2 weeks and antibiotics or bismuth 4 weeks before each test; retest ≥4 weeks after treatment
H. pylori negative, or eradicated but still symptomatic: PPI
- Standard dose once daily for 4‑8 weeks, e.g., omeprazole 20 mg
- Lowest effective dose; higher doses add no benefit
No response to PPI by 8‑12 weeks: neuromodulator
- Low-dose amitriptyline or nortriptyline at bedtime
- Mirtazapine at bedtime, especially with early satiation and weight loss
- Itopride or acotiamide add-on where available
Caution: Check each drug’s label for contraindications and interactions before starting; doses are in the article.
Refractory FD: add CBT or gut‑directed hypnotherapy
- Screen for anxiety, depression and eating disorders; refer to psychiatry or psychology if they significantly impair function or response
Still refractory: recheck before escalating
- Look for a missed diagnosis (e.g., duodenal biopsy)
- Confirm H. pylori eradication status; refer to a GI specialist
S4. First-Line Pharmacotherapy
Lifestyle and Dietary Modifications
Initial measures include smaller more frequent meals, slow eating with thorough chewing, avoidance of dietary triggers identified by patient (commonly fatty foods, spicy foods, caffeine, alcohol, carbonated beverages), weight loss in overweight patients (improves symptoms via reduced intra-abdominal pressure and accommodation), smoking cessation, stress management, and review of medications that may worsen symptoms (NSAIDs, bisphosphonates, iron, potassium chloride, calcium channel blockers, anticholinergics). Evidence for specific dietary interventions (low FODMAP, gluten-free) in FD is limited but may help selected patients with overlap IBS or celiac concerns.
Proton Pump Inhibitors
PPIs are first-line pharmacologic therapy for functional dyspepsia, particularly EPS subtype. Standard dose (omeprazole 20 mg PO daily, esomeprazole 20 mg PO daily, pantoprazole 40 mg PO daily, lansoprazole 30 mg PO daily, rabeprazole 20 mg PO daily) for 4-8 weeks provides symptomatic benefit with NNT of approximately 8-10. EPS responds preferentially; PDS shows less reliable response. Take 30-60 minutes before breakfast for optimal effect. If response is achieved, taper to lowest effective dose or step down to H2 receptor antagonist (famotidine 20-40 mg PO daily). Long-term continuous PPI requires periodic reassessment given concerns about osteoporosis risk, B12 deficiency, increased C. difficile, and possible CKD progression.
Prokinetics for PDS
| Drug | Dose | Cautions |
|---|---|---|
| Metoclopramide | 5-10 mg PO TID 30 min before meals + bedtime | FDA BLACK BOX: tardive dyskinesia; limit to 12 weeks; avoid Parkinson disease |
| Itopride (where available) | 50 mg PO TID before meals | D2 antagonist + AChE inhibitor; better tolerated than metoclopramide; not FDA-approved in US |
| Domperidone (limited availability) | 10 mg PO TID before meals | QT prolongation risk; obtain ECG; avoid in known QT prolongation, electrolyte disturbance, or interacting medications; not FDA-approved (FDA expanded access) |
| Acotiamide (Japan) | 100 mg PO TID before meals | AChE inhibitor + M1/M2 antagonist; approved for PDS in Japan; favorable tolerability |
| STW 5 (Iberogast, herbal) | 20 drops PO TID before meals | Multi-herb preparation; supportive evidence; favorable safety; available OTC in many countries |
| Erythromycin | NOT recommended | Tachyphylaxis; QT prolongation; antibiotic stewardship concerns |
Treatment Algorithm by Subtype
| Subtype | First-line | Second-line | Refractory |
|---|---|---|---|
| EPS (epigastric pain) | PPI 4-8 weeks; H. pylori test-and-treat if positive | Add or switch to TCA (amitriptyline 10-25 mg qHS) | Combine PPI + TCA + behavioral therapy; consider clinical trial |
| PDS (postprandial) | Prokinetic (metoclopramide, itopride, domperidone) + dietary modification | Add buspirone (10 mg TID); H. pylori test-and-treat if positive | Mirtazapine 7.5-15 mg qHS for nausea/early satiation/weight loss; behavioral therapy |
| Overlap PDS + EPS | PPI + prokinetic | Add TCA or mirtazapine; H. pylori test-and-treat if positive | Combination triple therapy + behavioral therapy |
| FD with significant nausea/weight loss | Mirtazapine 7.5-15 mg qHS first-line; prokinetic | Nutritional consultation; gastric emptying study to exclude gastroparesis | Subspecialty referral; consider gastric electrical stimulation |
S5. Refractory Disease and Neuromodulators
Tricyclic Antidepressants
Tricyclic antidepressants are second-line for refractory FD, particularly EPS subtype. Amitriptyline 10-50 mg PO at bedtime or nortriptyline 10-50 mg PO at bedtime work through gut-brain axis modulation, central pain inhibition, and improvement of visceral hypersensitivity at doses lower than antidepressant doses. The FUNCTIONAL trial showed amitriptyline significantly reduced symptoms versus placebo and escitalopram in FD, with NNT approximately 6 for global improvement. Start low and titrate every 1-2 weeks based on response and tolerability. Common side effects include drowsiness (taking at bedtime mitigates), dry mouth, constipation, and orthostatic dizziness; nortriptyline has less anticholinergic burden than amitriptyline. Avoid in patients with significant cardiac conduction disease or QT prolongation.
Mirtazapine
Mirtazapine 7.5-15 mg PO at bedtime is particularly useful for FD patients with prominent early satiation, nausea, and weight loss. Mechanisms include 5-HT3 antagonism (anti-nausea), histamine H1 antagonism (appetite stimulation, sleep), and central pain modulation. Studies demonstrate improvement in dyspepsia symptoms, reduction in nausea/vomiting, and weight gain in FD with weight loss. Side effects include sedation (use bedtime dosing) and weight gain (often desired). Useful for the malnourished, weight-losing patient where appetite stimulation is therapeutic rather than adverse.
Other Neuromodulators
| Drug | Mechanism | Dose | Notes |
|---|---|---|---|
| Buspirone | 5-HT1A agonist | 10 mg PO TID | Improves gastric accommodation in PDS; adjunct rather than monotherapy |
| SSRI (citalopram, sertraline) | Selective serotonin reuptake inhibition | Citalopram 10-20 mg PO daily | Less effective for FD specifically; useful for comorbid anxiety/depression |
| SNRI (duloxetine, venlafaxine) | Combined 5-HT and norepinephrine reuptake inhibition | Duloxetine 30-60 mg PO daily | Limited FD-specific data; consider for chronic pain overlap |
| Pregabalin | Calcium channel modulator | 75 mg PO BID | Off-label; emerging data for visceral hypersensitivity |
S6. Behavioral Therapy and Long-Term Care
Brain-Gut Behavioral Therapies
Brain-gut behavioral therapies are effective for refractory FD with NNT of approximately 4-6 for global symptom improvement. Cognitive behavioral therapy addresses maladaptive symptom-related thoughts and behaviors (food avoidance, fear-driven dietary restriction, restroom-mapping behavior in overlap with IBS). Gut-directed hypnotherapy uses guided imagery focused on gastric function and sensation, typically delivered in 7-12 sessions. Mindfulness-based stress reduction and yoga have supportive evidence for stress-related symptom modulation. Digital and app-based programs (e.g., Mahana FD analogs, Zemedy) increase access where in-person GI psychology is unavailable.
Psychiatric Comorbidity
Anxiety, depression, somatization, history of trauma, and eating disorders are common in FD and contribute to symptom severity, healthcare utilization, and treatment refractoriness. Screening tools (PHQ-9, GAD-7, somatization) identify patients who would benefit from focused psychiatric care. Antidepressant therapy may serve dual purpose: treating both psychiatric comorbidity and dyspepsia. Refer to psychiatry or psychology when comorbidity significantly impacts function or response to standard FD therapy.
Long-Term Course and Surveillance
FD is typically a relapsing-remitting condition over years to decades, with approximately 50% of patients reporting persistent symptoms over 10 years and 30% continuing to seek care. Patients at higher risk of chronic course include those with severe baseline symptoms, female sex, anxiety/depression, history of infection-triggered onset, and overlap with IBS or other functional GI disorders. Periodic reassessment (every 6-12 months) of symptom subtype (which can shift), severity, treatment response, and quality of life impact guides therapeutic adjustments. New or worsening alarm features (weight loss, dysphagia, bleeding, mass, age >60 with symptom change) warrant repeat endoscopy.
Areas of Uncertainty
The role of duodenal eosinophilia and mast cell activation as therapeutic targets is evolving; emerging trials evaluate H1 and H2 antagonists, leukotriene modifiers, and mast cell stabilizers. Rifaximin’s role in FD (analogous to its IBS-D indication) is investigational with mixed results. Vonoprazan (PCAB class) has expanding data for both EPS-predominant FD and as a more potent acid suppressant alternative to PPI. Pyloric interventions (POP — peroral pyloromyotomy, G-POEM) for refractory PDS with gastroparesis-overlap features show promise but optimal patient selection remains unclear. Microbiome-targeted therapies (probiotics, FMT) lack robust FD-specific evidence.
S7. Practice Insights: Subtype-Specific Therapy Determines Whether the Patient Returns
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)A normal endoscopy is handed over as reassurance and the visit ends there, when in functional dyspepsia that result is where classification should begin — this disease is mismanaged in one specific direction: every patient gets PPI as a reflex, and the postprandial distress syndrome (PDS) patients return month after month because acid was never the dominant pathophysiology. In experienced practice, the Rome IV subtype distinction — PDS versus EPS — drives every downstream decision, and the patients experienced clinicians see relapsing are those whose subtype was never formally classified. The single question to ask at every functional dyspepsia visit is: “Are the symptoms postprandial or epigastric pain at any time?”
The Subtype Distinction That Changes Therapy
Postprandial distress syndrome (PDS, 60-70%) — bothersome postprandial fullness or early satiation occurring after meals — responds to prokinetics (mosapride, acotiamide where available, metoclopramide short-term) and motility-modulating agents, not acid suppression. Epigastric pain syndrome (EPS, 20-30%) — burning epigastric pain unrelated to meals — responds to PPI as first-line. Mixed PDS+EPS (10-20%) needs both arms. In experienced hands, the most common diagnostic-therapy mismatch is the PDS patient on PPI monotherapy for 6 months without improvement — switching to a prokinetic produces meaningful response in roughly 50-60% of these patients.
H. pylori Test-and-Treat Discipline Seasoned Clinicians Maintain
The Maastricht VI consensus and ACG guidelines support test-and-treat strategy for H. pylori in all functional dyspepsia patients. In practice, every functional dyspepsia patient gets H. pylori testing — urea breath test or stool antigen, with at least 2 weeks off PPI before testing (4 weeks ideal). H. pylori eradication produces meaningful symptom resolution in roughly 10-15% of FD patients at 12 months, which is small but real, and importantly removes a confounding diagnosis. Experienced clinicians have stopped accepting “PPI as empiric trial” before H. pylori testing — false-negative testing on PPI is a common workup failure.
The Neuromodulator Decision Experienced Practitioners Make Earlier Than Many
For refractory FD (failure of PPI ± prokinetic at 8-12 weeks), the preferred neuromodulator is amitriptyline 10-25 mg at bedtime or mirtazapine 7.5-15 mg at bedtime — the latter particularly for PDS with weight loss/early satiety because mirtazapine’s appetite-stimulating effect helps. Experienced practice adds the neuromodulator at the 8-12 week mark, not at 6 months, because the slow response (4-8 weeks to effect) means delayed initiation extends the symptomatic period unnecessarily. Experienced clinicians avoid SSRIs as first-line neuromodulator for FD because the evidence base is weaker and they can worsen nausea in PDS.
Endoscopy — Where Seasoned Clinicians Lower the Threshold
Standard guidelines advise endoscopy for FD with alarm features or age over 60 (45-55 in some). In experienced practice experienced practitioners lower this threshold meaningfully: endoscopy for any patient over 50 with new-onset symptoms, anyone with weight loss greater than 5% in 6 months, any iron deficiency anemia, persistent vomiting, family history of gastric cancer under age 50, or symptoms not responding to 8-12 weeks of subtype-directed therapy. Younger patients with classic FD without alarms can be managed without endoscopy, but in regions with high gastric cancer prevalence (Korea, Japan, parts of South America) the established threshold is even lower — experienced practice orders endoscopy for almost all new presentations.
Illustrative Scenario — PDS Misdiagnosed as Acid Reflux for 18 Months
A woman in her mid-forties was referred to the treating clinicians for “refractory GERD” after 18 months on omeprazole 40 mg twice daily without improvement. Her actual symptoms on direct questioning: bothersome postprandial fullness within 30 minutes of eating, early satiety preventing completion of normal meals, no heartburn, no regurgitation. Endoscopy was normal; H. pylori urea breath test was negative (off PPI for 4 weeks); celiac serology, thyroid, and basic labs were normal. The Rome IV criteria fit postprandial distress syndrome cleanly, with no overlap into EPS. The treating clinicians discontinued the PPI, started mosapride 5 mg three times daily before meals, and counseled on small-frequent meals plus fat reduction. At 6-week follow-up she reported substantial improvement, no longer felt full after small meals, and weight had stabilized after 18 months of involuntary loss. They added mirtazapine 7.5 mg at bedtime for the residual early satiety; at 12-week follow-up symptoms were largely resolved.
the established Protocol Adjustments to Standard FD Management
- Rome IV subtype classification before first-line therapy: PDS gets prokinetic first, EPS gets PPI first, mixed gets both. Do not default to PPI empirically — the wrong arm at first-line predicts non-response and patient dissatisfaction.
- H. pylori test-and-treat in all FD patients (off PPI 2-4 wk): UBT or stool antigen, not serology. Eradication helps 10-15% at 12 mo, removes a confounding diagnosis, and prevents future complications.
- Neuromodulator initiation at 8-12 weeks of first-line failure, not 6 months: Amitriptyline 10-25 mg qhs or mirtazapine 7.5-15 mg qhs (preferred in PDS with weight loss). Slow response (4-8 wk) means earlier start matters.
- Lower endoscopy threshold in Asian populations and any new symptoms over 50: Gastric cancer prevalence justifies broader scoping. Younger patients with classic FD without alarms can be managed without endoscopy, but the regional epidemiology is the swing factor.
Frequently Asked Questions
What are the Rome IV criteria for functional dyspepsia?
When is upper endoscopy indicated in patients with dyspepsia?
What is the H. pylori test-and-treat strategy for functional dyspepsia?
What is the role of PPIs in functional dyspepsia?
What prokinetics are useful for postprandial distress syndrome?
What is the role of neuromodulators in refractory functional dyspepsia?
How does functional dyspepsia differ from gastroparesis and chronic nausea?
- Chronic Constipation: ACG/AGA Diagnosis, Rome IV Criteria, and Stepwise Medical Therapy
- Helicobacter pylori Infection — Diagnosis and Eradication Therapy
- Cholangiocarcinoma: Anatomic Classification, Targeted Therapy, and Liver Transplant Pathway
- Microscopic Colitis: Diagnosis, Budesonide Therapy, and Management
- Primary Biliary Cholangitis: Diagnosis and Second-Line Therapy
- Wilson Disease: Leipzig Diagnostic Score, Chelation Therapy, and Long-Term Management
Primary guideline documents this article draws on. Links resolve via DOI to the publisher; access may require a subscription.
- ACG Clinical Guideline: Treatment of Helicobacter pylori Infection (American Journal of Gastroenterology · 2024)
- Maastricht VI/Florence consensus — Management of Helicobacter pylori infection (Gut · 2022)
- ACG/CAG 2017 Clinical Guideline: Management of Dyspepsia (American Journal of Gastroenterology · 2017)